Redcare Pharmacy NV (HAM:RDC) Research & Development: €0 Mil (TTM As of Mar. 2026)


HAM:RDC Redcare Pharmacy NV HAM:RDC
14 GF Score
Price €64.85
GF Value €179.32
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Redcare Pharmacy NV Research & Development?

Redcare Pharmacy NV HAM:RDC -1.52% 14 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates HAM:RDC with a GF Score™ of 14/100 and a GF Value™ of €179.32 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Redcare Pharmacy NV's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Redcare Pharmacy NV  (HAM:RDC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Redcare Pharmacy NV Research & Development Related Terms

Redcare Pharmacy NV Research & Development Historical Data

* Premium members only.

The historical data trend for Redcare Pharmacy NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redcare Pharmacy NV Research & Development Chart

Redcare Pharmacy NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Redcare Pharmacy NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:RDC
14GF Score
Redcare Pharmacy NV HAM:RDC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Redcare Pharmacy NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Redcare Pharmacy NV (HAM:RDC) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Redcare Pharmacy NV and its competitors.
Is Redcare Pharmacy NV's Research & Development too high?
Redcare Pharmacy NV's current Research & Development is €0 Mil. Overall, Redcare Pharmacy NV has a GF Score™ of 14/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Redcare Pharmacy NV's Research & Development compare to competitors?
Redcare Pharmacy NV's Research & Development of €0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Redcare Pharmacy NV and its competitors. Redcare Pharmacy NV's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redcare Pharmacy NV stock overvalued right now?
Based on GuruFocus' analysis, Redcare Pharmacy NV (HAM:RDC) is currently considered Significantly Undervalued. The stock's GF Value™ is €179.32, compared to a current price of €64.85 — trading 63.8% below its estimated fair value. The current Research & Development is €0 Mil. Redcare Pharmacy NV's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Redcare Pharmacy NV (HAM:RDC), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Redcare Pharmacy NV (HAM:RDC) Overvalued in 2026?

Based on GuruFocus' analysis, Redcare Pharmacy NV stock appears to be undervalued. The current stock price of €64.85 is trading 63.8% below its estimated GF Value™ of €179.32. GuruFocus considers Redcare Pharmacy NV to be Significantly Undervalued.

Key valuation signals for HAM:RDC:

  • Research & Development: €0 Mil
  • GF Value™: €179.32 vs. price of €64.85 (63.8% below fair value)
  • GF Score™: 14/100 with 2 warning signs

No single metric tells the full story. See the HAM:RDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Redcare Pharmacy NV Business Description

Address Erik de Rodeweg 11/13, Sevenum, ZH, NLD, 5975 WD
Redcare Pharmacy NV is an online pharmacy business for prescription and nonprescription (over-the-counter) pharmaceuticals, beauty and personal care products (BPC) and food supplements. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. It operates in two segments, namely DACH segment that includes sales in Germany, Austria and Switzerland; and the International segment that includes sales across Belgium, the Netherlands, France and Italy. The DACH segment accounts for the majority of the revenue.
14GF Score

Get the complete analysis for HAM:RDC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.85
Price
€179.32
GF Value